Provided By GlobeNewswire
Last update: Aug 5, 2025
SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its second quarter ended June 30, 2025.
Read more at globenewswire.comNASDAQ:RXRX (9/8/2025, 12:17:39 PM)
4.635
+0.02 (+0.54%)
Find more stocks in the Stock Screener